Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2000-07-05
2009-11-24
Jung, Unsu (Department: 1641)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007900, C435S007910, C435S007920, C435S069100, C435S069600, C435S070300, C436S501000, C436S504000, C436S517000, C436S518000, C436S528000, C436S164000, C436S172000, C436S805000, C436S819000
Reexamination Certificate
active
07622259
ABSTRACT:
The present invention relates to a method for detecting von-Willebrand factor (vWF) activity comprising assaying a sample in the presence of a soluble form or portion of glycoprotein Ib(α) (GPIb(α) and ristocetin, or a functionally equivalent substance. Additionally, the invention relates to the use of the aforementioned soluble form or portion of glycoprotein Ib(α), of ristocetin or a functional equivalent substance, of specifically reacting anti-GPIB(α) antibody(ies) and/or of specific binding partners, like specifically reacting anti-vWF antibody(ies) for carrying out the method of the invention. Furthermore, the present invention relates to kits for carrying out the method of the invention.
REFERENCES:
patent: 4415700 (1983-11-01), Batz et al.
patent: 4537861 (1985-08-01), Elings et al.
patent: 5231033 (1993-07-01), Fickenscher
patent: 5317097 (1994-05-01), Miller et al.
patent: 5321127 (1994-06-01), Handin
patent: 5837488 (1998-11-01), Garfinkel et al.
patent: 6043871 (2000-03-01), Solen et al.
patent: 6228613 (2001-05-01), Fischer et al.
patent: 92/16225 (1992-10-01), None
patent: 01/02853 (2001-01-01), None
Murata, M. et al., “Site-directed mutagenesis of a soluble recombinant fragment of platelet glycoprotein Iba demonstrating negatively charged residues involved in von Willebrand factor binding”, 1991, J Biol Chem, vol. 266, pp. 15474-15480.
Favaloro et al., “Von-Willebrand's diseas: laboratory investigation using an improved functional assay for von Willebrand factor”, Pathology, 1993, vol. 25, pp. 152-158.
Hoylaerts et al., “Promotion of binding of von Willebrand factor ot platelet glycoprotein by dimers of ristocetin”, Biochem. J., 1995, vol. 386, pp. 453-463.
Christophe et al., “Influence of Mutations and Size of Multimers in Type II von Willebrand Disease Upon the Function of von Willebrand Factor”, Blood, 1994, vol. 83, pp. 3553-3561.
Favaloro, “Laboratory assessment as a critical component of the appropriate diagnosis and sub-classification of von Willebrand's disease”, Blood Review, 1999, vol. 13, pp. 185-204.
Michelson et al., “Partial characterization of a binding site for von Willebrand factor on glycocalicin”, Blood, 1986, vol. 67, pp. 19-26.
Vanhoorelbeke et al., “Plasma glycocalicin as a source of GP1b-alpha in the von Willebrand factor ristocetin cofactor ELISA”, Thromb. Haemost., 2005, vol. 93, pp. 165-171.
Murray et al., “von Willebrand disease: pathogenesis, classification, and management,” Transfusion Medicine Reviews, 1996, vol. X, pp. 93-110.
Tefferi et al., “Acquired von Willebrand disease: concise review of occurrence, diagnosis, pathogenesis, and treatment,” Am. J. Med., 1997, vol. 103, pp. 536-540.
Vischer et al, “von Willebrand factor: from cell biology to the clinical management of von Willebrand's disease,” Critical Reviews in Oncology/Hematology, 1999, vol. 30, pp. 93-109.
Zieger et al, “New families with von Willebrand disease type 2M (Vicenza),” Thrombosis Research, 1997, vol. 87, pp. 57-64.
Aihara et al., (1988), “Plasma Collagen Cofactor Correlates with von Willebrand Factor Antigen and Ristocetin Cofactor but Not with Bleeding Time,”Thromb. Haemost., 59(3):485-490.
Berliner et al., (1988), Generation and Characterization of Peptide-specific Antibodies That Inhibit Von Willebrand Factor Binding to Glycoprotein IIb-IIIa without Interacting with Other Adhesive Molecules,J. Bio. Chem., 263:7500-7505.
Brown et al., (1986), “An ELISA Test for the Binding of von Willebrand Antigen to Collagen,”Thromb Res., 43:303-311.
Casonato et al., (1998), “The Evaluation of Factor VIII Binding Activity of von Willebrand Factor by Means of an ELISA Method, Significance and Practical Implications,”Am. J. Clin. Path., 109:347-352.
De Marco et al., (1986), “von Willebrand Factor Interaction with the Glycoprotein IIb/IIIa Complex, Its role in Platelet Function as Demonstrated in Patients with Congenital Afibrinogenemia,”J. Clin. Invest., 77:1272-1277.
Depraetere et al., (1988), “Platelet Aggregation Induced by a Monoclonal Antibody of the A1 Domain of von Willebrand Factor,”Blood, 91:3792-3799.
Ewenstein, (1997), “Von Willebrand's Disease,”Annu. Rev. Med., 48:525-542.
Falkenberg et al., (1995), “In vitro production monoclonal antibodies in high concentration in a new and easy to handle modular minifermenter,”J. Immunol, Methods, 179:13-29.
Favalore et al., (1991), “Development of a simple collagen based ELISA assay aids in the diagnosis of, and permits sensitive discrimination between Type I and Type II, von Willebrand's disease,”Blood Coagul. Fibrinolysis, 2:285-291.
Favaloro et al., (1993), “von Willebrand's Disease: Laboratory Investigation Using an Improved Functional Assay for von Willebrand Factor,”Pathology, 25:152-158.
Favaloro et al., (1995), “Laboratory Assessment of von Willebrand Factor, Use of Different Assays Can Influence the Diagnosis of von Willebrand's Disease, Dependent on Differing Sensitivity to Sample Preparation and Differential Recognition of High Molecular Weight VWF Forms,”Am. J. Clin. Pathol., 104:(3)264-271.
Favaloro et al, (1997), “Laboratory Assays For von Willebrand Factor: Relative Contribution to the Diagnosis of von Willebrand's Disease,”Pathology, 29:385-91.
Federici et al., (1989), “Binding of von Willebrand factor to glycoproteins Ib and IIb/IIIa complex: affinity is related to multimeric size,”Br. J. Haemato., 73:93-99.
Federici et al., (2004), “A sensitive ristocetin co-factor activity assay with recombinant glycoprotein Ibα for the diagnosis of patients with low von Willebrand factor levels,”Haematologica, 89:77-85.
Fischer et al., (1996), “Effect of Multimerization of Human and Recombinant von Willebrand Factor on Platelet Aggregation, Binding to Collagen and Binding of Coagulation Factor VIII,”Thromb. Res., 84(1):55-66.
Fischer et al., (1998), “von Willebrand Factor: Measuring its Antigen or Function? Correlation between the Level of Antigen, Activity, and Multimer Size using Various Detection systems,”.Thromb. Res., 91:39-43.
Furlan et al, (1985), “Reactivity of Small Molecular Forms of Human Factor VII/von Willebrand Factor with Botrocetin and Anti-Factor VIII-Coated Latex Particles,”Thromb. Haemost., 54(2):463-465.
Galfre et al, (1981), “Preparation of Monoclonal Antibodies: Strategies and Procedures,”Meth. Enzymol., 73:3-46.
Harsfalvi etal., (1995), “Calin From Hirudo Medicinalis, an Inhibitor of von Willebrand Factor Binding to Collagen Under Static and Flow Conditions,”Blood, 85(3):705-711.
Howard et al., (1971), “Ristocetin-A New Tool in the Investigation of Platelet Aggregation,”Thromb. Diath. Haemorrh., 26:362-369.
Hoylaerts et al., (1995), “Promotion of binding of von Willebrand factor to platelet glycoprotein Ib by dimers of ristocetin,”Biochem. J., 306:453-463.
Hoylaerts et al., (1997), “von Willebrand factor binds to native callagen VI primary via its A1 domain,”Biochem. J., 324:185-191.
Ingerslev, (1987), A sensitive ELISA for von willebrand factor (vWf:Ag);Scand. J. Clin. Lab. Invest., 47:143-149.
Köhler et al., (1975), “Continuous cultures of fused cells secreting antibody of predefined specificity,”Nature, 256:495-497.
Lankhof et al, (1996), “A3 Domain Is Essential for Interaction of von Willebrand Factor with Collagen Type III,”Thromb. Haemost., 75:950-958.
Li et al., (2001), “Expression of the Amino-Terminal Domain of Platelet Glycoprotein Ibα: Exploitation of a Calmodulin Tag for Determination of Its Functional Cavity,”Protein Expression and Purification, 22:200-210.
Macfarlane et al., (1975), “A Method for Assaying von Willebrand Factor (Ristocetin Cofactor),”T
Cauwenberghs Nancy
Deckmyn Hans
Vanhoorelbeke Karen
Burns & Levinson LLP
Jung Unsu
K.U. Leuven Research & Development
Moore Ronda P.
LandOfFree
Detection of von-Willebrand factor (vWF) activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Detection of von-Willebrand factor (vWF) activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Detection of von-Willebrand factor (vWF) activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4092654